Lilly doubles down on radiopharma
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Category: Pharmaceuticals
STAT+: AltruBio raises $225 million to develop ulcerative colitis drug and other immune checkpoint enhancers
Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have…
AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk,…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Lawmaker accuses Amgen of placing profits above patients with dosing for a cancer drug
A U.S. lawmaker is accusing Amgen of “putting profits before patients” over its decision to…
STAT+: Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease,…
Is Novavax a new meme stock?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sandoz leaves U.K. trade group over dispute about promoting a biosimilar for multiple sclerosis
In an unusual move, Sandoz is no longer cooperating with a U.K. industry trade group…
We now know Tome’s gene editing target
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: FDA is criticized for taking a ‘ministerial’ role in sorting out some pharma patents
When it comes to a crucial controversy over pharmaceutical patents, the FDA has been MIA….
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Sanofi enters vaccine licensing deal with Novavax, giving beleaguered biotech a lifeline
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pharma has over $500B in capital for deals
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Young boy dies in trial for Pfizer Duchenne gene therapy
A young boy died in a trial for Pfizer’s experimental gene therapy for Duchenne muscular…
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: The world is relying on the United States to get value-based drug pricing right
The changing landscape of drug pricing policy in the U.S. has implications for the global…
Merck may have a competition for ever-scarce BCG
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Creating the next wave of antibody therapies requires innovative collaboration
Next-generation broadly neutralizing antibodies (bnAbs) have the potential to transform the fight against global health…
FDA wants to hear your thoughts on advisory committees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Federal judge rules against two drugmakers challenging Medicare drug price negotiation program
WASHINGTON — A federal judge in New Jersey on Monday dealt a blow to two…
STAT+: Pharma’s reputation with patient groups is sliding again thanks to prices and shortages
The pharmaceutical industry saw its reputation slip last year among patient advocacy groups thanks to…
STAT+: Doctors Without Borders challenges pharma by releasing costs for a key clinical trial
In a challenge to the pharmaceutical industry, Doctors Without Borders has revealed the detailed costs…
.jpg)
Opinion: Shortages of generic drugs can’t be blamed solely on group purchasing organizations
The Hatch-Waxman Act of 1984, which gave rise to the modern generic drug market, was…
STAT+: Takeda is fourth big company to leave BIO since December
WASHINGTON — Takeda Pharmaceuticals has left the biotechnology industry’s main lobbying group, the fourth departure…
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
Two years after biosimilars became available in the U.S., a higher proportion of patients using…
STAT+: Novo Nordisk’s move to discontinue an insulin leaves patients to ‘pick up the pieces’
A year ago, when Novo Nordisk announced it would cut the price of multiple insulin…
STAT+: Looking for signs of growth in Biogen’s earnings
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk’s growth plan
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: How a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth
Makena, once the only available treatment to prevent preterm birth, has had its share of…
Opinion: Moving the conversation about obesity beyond the scale
Every so often, the conversations that people in health care have become so pervasive that…
STAT+: Animal rights group urges SEC to investigate Charles River over monkey purchases
A leading animal rights group has asked securities regulators to investigate Charles River Laboratories for…
Amylyx’s Relvyvrio data was, as promised, disappointing
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Biohaven’s data delay degrades stock price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Chuck Schumer’s broken promise on affordable insulin
WASHINGTON — In February 2022, Senate Majority Leader Chuck Schumer stood alongside constituents in Buffalo,…
A two-decade bet on Seagen pays off
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
What about the company Vertex didn’t buy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too…
European regulators find no evidence of link between new obesity medicines and suicidal thoughts
LONDON — Following a nine-month investigation, European regulators said Friday they have found no evidence…
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: European Parliament votes in favor of updated pharma legislation, prompting mixed reactions
The European Parliament has voted overwhelmingly to adopt legislation that is supposed to transform the…
STAT+: Medicare expects to spend $3.5 billion on new Alzheimer’s drug in 2025
Medicare for the first time has estimated that a new Alzheimer’s treatment could cost the…